Programmed Necrosis in the Cross Talk of Cell Death and Inflammation
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Potential Role of Necroptosis in Clinical Diseases (Review)
INTERNATIONAL JOURNAL OF MOleCular meDICine 47: 89, 2021 The potential role of necroptosis in clinical diseases (Review) WENLI DAI1*, JIN CHENG1*, XI LENG2, XIAOQING HU1 and YINGFANG AO1 1Institute of Sports Medicine, Beijing Key Laboratory of Sports Injuries, Peking University Third Hospital, Beijing 100191; 2Medical Imaging Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, P.R. China Received November 19, 2020; Accepted March 8, 2021 DOI: 10.3892/ijmm.2021.4922 Abstract. As an important type of programmed cell death in 1. Introduction addition to apoptosis, necroptosis occurs in a variety of patho‑ physiological processes, including infections, liver diseases, Necroptosis, an emerging field closely related to apoptosis, is a kidney injury, neurodegenerative diseases, cardiovascular non‑caspase‑dependent cell death that has been implicated in diseases, and human tumors. It can be triggered by a variety the pathological processes of various diseases. It is regulated of factors, such as tumor necrosis factor receptor and Toll‑like by various genes that cause regular and ordered cell death. receptor families, intracellular DNA and RNA sensors, and Through activating specific death signaling pathways, it shares interferon, and is mainly mediated by receptor‑interacting typical characteristics of necrosis, including loss of metabolic protein kinase 1 (RIP1), RIP3, and mixed lineage kinase function and subcellular changes (1,2). Receptor‑interacting domain‑like protein. A better understanding of the mechanism protein kinase 1 (RIP1) was the first signaling molecule of necroptosis may be useful in the development of novel drugs identified in the necrosome (3). RIP1 and RIP3 interact for necroptosis‑related diseases. -
HAC-1, a Drosophila Homolog of APAF-1 and CED-4, Functions in Developmental and Radiation-Induced Apoptosis
Molecular Cell, Vol. 4, 745±755, November, 1999, Copyright 1999 by Cell Press HAC-1, a Drosophila Homolog of APAF-1 and CED-4, Functions in Developmental and Radiation-Induced Apoptosis Lei Zhou, Zhiwei Song,² Jan Tittel,² generation of a large (p20) and small (p10) subunit. Cas- and Hermann Steller* pases can be activated through cleavage by active ªiniti- Howard Hughes Medical Institute atorº caspases in a caspase cascade (Li et al., 1997), Department of Biology and by autoproteolysis following aggregation of two or Massachusetts Institute of Technology more zymogen molecules (MacCorkle et al., 1998; Muzio Cambridge, Massachusetts 02139 et al., 1998; Yang et al., 1998). Upon activation of ªexecu- tionerº caspases, a wide variety of specific intracellular proteins are cleaved in different cellular compartments, and it is thought that their breakdown ultimately leads to Summary the characteristic morphological changes of apoptosis (Nicholson and Thornberry, 1997). The activation of cas- We have identified a Drosophila homolog of Apaf-1 pases appears to be tightly controlled by both positive and ced-4, termed hac-1. Like mammalian APAF-1, HAC-1 can activate caspases in a dATP-dependent and negative regulators. On the one hand, members of manner in vitro. During embryonic development, hac-1 the IAP (inhibitor of apoptosis protein) family can inhibit is prominently expressed in regions where cells un- caspases and apoptosis in a variety of insect and verte- dergo natural death. Significantly, hac-1 transcription brate systems (Uren et al., 1998; Deveraux and Reed, is also rapidly induced upon ionizing irradiation, similar 1999). On the other hand, caspase activation is stimu- to the proapoptotic gene reaper. -
RT² Profiler PCR Array (384-Well Format) Human Apoptosis 384HT
RT² Profiler PCR Array (384-Well Format) Human Apoptosis 384HT Cat. no. 330231 PAHS-3012ZE For pathway expression analysis Format For use with the following real-time cyclers RT² Profiler PCR Array, Applied Biosystems® models 7900HT (384-well block), Format E ViiA™ 7 (384-well block); Bio-Rad CFX384™ RT² Profiler PCR Array, Roche® LightCycler® 480 (384-well block) Format G Description The Human Apoptosis RT² Profiler PCR Array profiles the expression of 370 key genes involved in apoptosis, or programmed cell death. The array includes the TNF ligands and their receptors; members of the bcl-2 family, BIR (baculoviral IAP repeat) domain proteins, CARD domain (caspase recruitment domain) proteins, death domain proteins, TRAF (TNF receptor-associated factor) domain proteins and caspases. These 370 genes are also grouped by their functional contribution to apoptosis, either anti-apoptosis or induction of apoptosis. Using real-time PCR, you can easily and reliably analyze expression of a focused panel of genes related to apoptosis with this array. For further details, consult the RT² Profiler PCR Array Handbook. Sample & Assay Technologies Shipping and storage RT² Profiler PCR Arrays in formats E and G are shipped at ambient temperature, on dry ice, or blue ice packs depending on destination and accompanying products. For long term storage, keep plates at –20°C. Note: Ensure that you have the correct RT² Profiler PCR Array format for your real-time cycler (see table above). Note: Open the package and store the products appropriately immediately -
Cytokine Nomenclature
RayBiotech, Inc. The protein array pioneer company Cytokine Nomenclature Cytokine Name Official Full Name Genbank Related Names Symbol 4-1BB TNFRSF Tumor necrosis factor NP_001552 CD137, ILA, 4-1BB ligand receptor 9 receptor superfamily .2. member 9 6Ckine CCL21 6-Cysteine Chemokine NM_002989 Small-inducible cytokine A21, Beta chemokine exodus-2, Secondary lymphoid-tissue chemokine, SLC, SCYA21 ACE ACE Angiotensin-converting NP_000780 CD143, DCP, DCP1 enzyme .1. NP_690043 .1. ACE-2 ACE2 Angiotensin-converting NP_068576 ACE-related carboxypeptidase, enzyme 2 .1 Angiotensin-converting enzyme homolog ACTH ACTH Adrenocorticotropic NP_000930 POMC, Pro-opiomelanocortin, hormone .1. Corticotropin-lipotropin, NPP, NP_001030 Melanotropin gamma, Gamma- 333.1 MSH, Potential peptide, Corticotropin, Melanotropin alpha, Alpha-MSH, Corticotropin-like intermediary peptide, CLIP, Lipotropin beta, Beta-LPH, Lipotropin gamma, Gamma-LPH, Melanotropin beta, Beta-MSH, Beta-endorphin, Met-enkephalin ACTHR ACTHR Adrenocorticotropic NP_000520 Melanocortin receptor 2, MC2-R hormone receptor .1 Activin A INHBA Activin A NM_002192 Activin beta-A chain, Erythroid differentiation protein, EDF, INHBA Activin B INHBB Activin B NM_002193 Inhibin beta B chain, Activin beta-B chain Activin C INHBC Activin C NM005538 Inhibin, beta C Activin RIA ACVR1 Activin receptor type-1 NM_001105 Activin receptor type I, ACTR-I, Serine/threonine-protein kinase receptor R1, SKR1, Activin receptor-like kinase 2, ALK-2, TGF-B superfamily receptor type I, TSR-I, ACVRLK2 Activin RIB ACVR1B -
Dectin-1-Induced RIPK1 and RIPK3 Activation Protects Host Against Candida Albicans Infection
Cell Death & Differentiation (2019) 26:2622–2636 https://doi.org/10.1038/s41418-019-0323-8 ARTICLE Dectin-1-induced RIPK1 and RIPK3 activation protects host against Candida albicans infection 1 1 1 1 1 1 1 1 1 Mengtao Cao ● Zhengxi Wu ● Qi Lou ● Wenli Lu ● Jie Zhang ● Qi Li ● Yifan Zhang ● Yikun Yao ● Qun Zhao ● 1 1 1,2 Ming Li ● Haibing Zhang ● Youcun Qian Received: 5 November 2018 / Revised: 5 March 2019 / Accepted: 21 March 2019 / Published online: 3 April 2019 © ADMC Associazione Differenziamento e Morte Cellulare 2019 Abstract Necroptosis is a recently defined type of programmed cell death with the specific signaling cascade of receptor-interacting protein 1 (RIPK1) and RIPK3 complex to activate the executor MLKL. However, the pathophysiological roles of necroptosis are largely unexplored. Here, we report that fungus triggers myeloid cell necroptosis and this type of cell death contributes to host defense against the pathogen infection. Candida albicans as well as its sensor Dectin-1 activation strongly induced necroptosis in myeloid cells through the RIPK1-RIPK3-MLKL cascade. CARD9, a key adaptor in Dectin-1 signaling, was identified to bridge the RIPK1 and RIPK3 complex-mediated necroptosis pathway. RIPK1 and fl 1234567890();,: 1234567890();,: RIPK3 also potentiated Dectin-1-induced MLKL-independent in ammatory response. Both the MLKL-dependent and MLKL-independent pathways were required for host defense against C. albicans infection. Thus, our study demonstrates a new type of host defense system against fungal infection. Introduction antifungal drugs used in clinical application and increased drugs resistance, it is of great importance to investigate how Fungal infections severely influence human life quality host defenses against fungal infection to develop new and are common worldwide health problem. -
Table 2. Significant
Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S. -
Mutations in EDA and EDAR Genes in a Large Mexican Hispanic Cohort with Hypohidrotic Ectodermal Dysplasia
Letter to the Editor http://dx.doi.org/10.5021/ad.2015.27.4.474 Mutations in EDA and EDAR Genes in a Large Mexican Hispanic Cohort with Hypohidrotic Ectodermal Dysplasia Julio C Salas-Alanis1,2, Eva Wozniak3, Charles A Mein3, Carola C Duran Mckinster4, Jorge Ocampo-Candiani1, David P Kelsell5, Rong Hua6, Maria L Garza-Rodriguez7, Keith A Choate6, Hugo A Barrera Saldaña7,8 1Dermatology Department, Hospital Universitario, Universidad Autonoma de Nuevo Leon, 2Basic Science Department, Medicine School, Universidad de Monterrey, Monterrey, NL, Mexico, 3Barts and the London Genome Centre, John Vane Science Centre, Barts and the London School of Medicine and Dentistry, University of London, London, United Kingdom, 4Instituto Nacional de Pediatria, Coyoacan, CP, Mexico, 5Centre for Cutaneous Research, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, 6Departments of Dermatology, Genetics, and Pathology, Yale University School of Medicine, New Haven, CT, USA, 7Facultad de Medicina, Departamento de Bioquímica y Medicina Molecular, Universidad Autonoma de Nuevo Leon,8Vitagenesis, Monterrey, NL, Mexico Dear Editor: cludes dryness of the skin, eyes, airways, and mucous Ectodermal dysplasias (ED) encompass nearly 200 differ- membranes, as well as other ectodermal defects and, in ent genetic conditions identified by the lack, or dysgenesis, some cases, fever, seizures, and rarely, death. of at least two ectodermal derivatives, such as hair, nails, XL-HED is caused by mutations in the EDA gene, located teeth, and sweat glands. Hypohidrotic/anhidrotic ED (HED) on chromosome Xq12-q13.1, which encodes a signaling is the most frequent form of ED and it can be inherited as molecule of the tumor necrosis factor (TNF) superfamily. -
Necroptosis in Intestinal Inflammation and Cancer
biomolecules Review Necroptosis in Intestinal Inflammation and Cancer: New Concepts and Therapeutic Perspectives Anna Negroni 1,* , Eleonora Colantoni 2, Salvatore Cucchiara 2 and Laura Stronati 3 1 Division of Health Protection Technologies, ENEA, 00123 Rome, Italy 2 Maternal Infantile and Urological Sciences Department, Sapienza, University of Rome, 00161 Rome, Italy; [email protected] (E.C.); [email protected] (S.C.) 3 Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-06-3048-3623 Received: 3 September 2020; Accepted: 8 October 2020; Published: 10 October 2020 Abstract: Necroptosis is a caspases-independent programmed cell death displaying intermediate features between necrosis and apoptosis. Albeit some physiological roles during embryonic development such tissue homeostasis and innate immune response are documented, necroptosis is mainly considered a pro-inflammatory cell death. Key actors of necroptosis are the receptor-interacting-protein-kinases, RIPK1 and RIPK3, and their target, the mixed-lineage-kinase-domain-like protein, MLKL. The intestinal epithelium has one of the highest rates of cellular turnover in a process that is tightly regulated. Altered necroptosis at the intestinal epithelium leads to uncontrolled microbial translocation and deleterious inflammation. Indeed, necroptosis plays a role in many disease conditions and inhibiting necroptosis is currently considered a promising therapeutic strategy. In this review, we focus on the molecular mechanisms of necroptosis as well as its involvement in human diseases. We also discuss the present developing therapies that target necroptosis machinery. Keywords: programmed cell death; inflammation; cancer; intestinal diseases; inhibitors 1. Introduction Cell death is crucial during the development and maintenance of tissue homeostasis in multicellular organisms. -
HDAC Inhibition Activates the Apoptosome Via Apaf1 Upregulation
Buurman et al. Eur J Med Res (2016) 21:26 DOI 10.1186/s40001-016-0217-x European Journal of Medical Research RESEARCH Open Access HDAC inhibition activates the apoptosome via Apaf1 upregulation in hepatocellular carcinoma Reena Buurman, Maria Sandbothe, Brigitte Schlegelberger and Britta Skawran* Abstract Background: Histone deacetylation, a common hallmark in malignant tumors, strongly alters the transcription of genes involved in the control of proliferation, cell survival, differentiation and genetic stability. We have previously shown that HDAC1, HDAC2, and HDAC3 (HDAC1–3) genes encoding histone deacetylases 1–3 are upregulated in primary human hepatocellular carcinoma (HCC). The aim of this study was to characterize the functional effects of HDAC1–3 downregulation and to identify functionally important target genes of histone deacetylation in HCC. Methods: Therefore, HCC cell lines were treated with the histone deacetylase inhibitor (HDACi) trichostatin A and by siRNA-knockdown of HDAC1–3. Differentially expressed mRNAs were identified after siRNA-knockdown of HDAC1–3 using mRNA expression profiling. Findings were validated after siRNA-mediated silencing of HDAC1–3 using qRTPCR and Western blotting assays. Results: mRNA profiling identified apoptotic protease-activating factor 1 (Apaf1) to be significantly upregulated after HDAC inhibition (HLE siRNA#1/siRNA#2 p < 0.05, HLF siRNA#1/siRNA#2 p < 0.05). As a component of the apoptosome, a caspase-activating complex, Apaf1 plays a central role in the mitochondrial caspase activation pathway of apopto- sis. Using annexin V, a significant increase in apoptosis could also be shown in HLE (siRNA #1 p 0.0034) and HLF after siRNA against HDAC1–3 (Fig. -
Apoptotic Threshold Is Lowered by P53 Transactivation of Caspase-6
Apoptotic threshold is lowered by p53 transactivation of caspase-6 Timothy K. MacLachlan*† and Wafik S. El-Deiry*‡§¶ʈ** *Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute, and Departments of ‡Medicine, §Genetics, ¶Pharmacology, and Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 Communicated by Britton Chance, University of Pennsylvania School of Medicine, Philadelphia, PA, April 23, 2002 (received for review January 11, 2002) Little is known about how a cell’s apoptotic threshold is controlled Inhibition of the enzyme reduces the sensitivity conferred by after exposure to chemotherapy, although the p53 tumor suppres- overexpression of p53. These results identify a pathway by which sor has been implicated. We identified executioner caspase-6 as a p53 is able to accelerate the apoptosis cascade by loading the cell transcriptional target of p53. The mechanism involves DNA binding with cell death proteases so that when an apoptotic signal is by p53 to the third intron of the caspase-6 gene and transactiva- received, programmed cell death occurs rapidly. tion. A p53-dependent increase in procaspase-6 protein level al- lows for an increase in caspase-6 activity and caspase-6-specific Materials and Methods Lamin A cleavage in response to Adriamycin exposure. Specific Western Blotting and Antibodies. Immunoblotting was carried out by inhibition of caspase-6 blocks cell death in a manner that correlates using mouse anti-human p53 monoclonal (PAb1801; Oncogene), with caspase-6 mRNA induction by p53 and enhances long-term rabbit anti-human caspase-3 (Cell Signaling, Beverly, MA), mouse survival in response to a p53-mediated apoptotic signal. -
Die Another Way – Non-Apoptotic Mechanisms of Cell Death
ß 2014. Published by The Company of Biologists Ltd | Journal of Cell Science (2014) 127, 2135–2144 doi:10.1242/jcs.093575 COMMENTARY Die another way – non-apoptotic mechanisms of cell death Stephen W. G. Tait1,*, Gabriel Ichim1 and Douglas R. Green2,* ABSTRACT apoptosis-resistant cancer cells. In this Commentary, we discuss major forms of non-apoptotic programmed cell death, how they Regulated, programmed cell death is crucial for all multicellular intersect with one another and their occurrence and roles in vivo, organisms. Cell death is essential in many processes, including and we outline outstanding questions. Following this, we ask tissue sculpting during embryogenesis, development of the immune whether it really matter how a cell dies. Specifically, we focus on system and destruction of damaged cells. The best-studied form of how the mode of cell death impacts on immunity and programmed cell death is apoptosis, a process that requires inflammation. activation of caspase proteases. Recently it has been appreciated that various non-apoptotic forms of cell death also exist, such as Necroptosis necroptosis and pyroptosis. These non-apoptotic cell death Various stimuli can engage a non-apoptotic form of cell death called modalities can be either triggered independently of apoptosis or necroptosis (Degterev et al., 2005). Although morphologically are engaged should apoptosis fail to execute. In this Commentary, resembling necrosis, necroptosis differs substantially in that it is a we discuss several regulated non-apoptotic forms of cell death regulated active type of cell death (Galluzzi et al., 2011; Green including necroptosis, autophagic cell death, pyroptosis and et al., 2011). -
Human RIPK1 Deficiency Causes Combined Immunodeficiency and Inflammatory Bowel Diseases
Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases Yue Lia,1, Marita Führerb,1, Ehsan Bahramia,1, Piotr Sochac, Maja Klaudel-Dreszlerc, Amira Bouzidia, Yanshan Liua, Anna S. Lehlea, Thomas Magga, Sebastian Hollizecka, Meino Rohlfsa, Raffaele Concaa, Michael Fieldd, Neil Warnere,f, Slae Mordechaig, Eyal Shteyerh, Dan Turnerh,i, Rachida Boukarij, Reda Belbouabj, Christoph Walzk, Moritz M. Gaidtl,m, Veit Hornungl,m, Bernd Baumannn, Ulrich Pannickeb, Eman Al Idrissio, Hamza Ali Alghamdio, Fernando E. Sepulvedap,q, Marine Gilp,q, Geneviève de Saint Basilep,q,r, Manfred Hönigs, Sibylle Koletzkoa,i, Aleixo M. Muisee,f,i,t,u, Scott B. Snapperd,i,v,w, Klaus Schwarzb,x,2, Christoph Kleina,i,2, and Daniel Kotlarza,i,2,3 aDr. von Hauner Children’s Hospital, Department of Pediatrics, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, 80337 Munich, Germany; bThe Institute for Transfusion Medicine, University of Ulm, 89081 Ulm, Germany; cDepartment of Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics, The Children’s Memorial Health Institute, 04730 Warsaw, Poland; dDivision of Gastroenterology, Hepatology and Nutrition, Boston Children’s Hospital, Boston, MA 02115; eSickKids Inflammatory Bowel Disease Center, Research Institute, Hospital for Sick Children, Toronto, ON M5G1X8, Canada; fCell Biology Program, Research Institute, Hospital for Sick Children, Toronto, ON M5G1X8, Canada; gPediatric Gastroenterology, Hadassah University Hospital, Jerusalem 91120, Israel; hThe Juliet Keidan